In Brief: Boehringer Ingelheim
Executive Summary
Boehringer Ingelheim: Invests additional $10 mil. in Cambridge Neuroscience common stock. Boehringer Ingelheim will acquire 1.24 mil. shares at $8.08 per share, giving the company 17% ownership of CNSI upon closing. Cambridge Neuroscience began a 900-patient pivotal trial of Cerestat (aptiganel) in stroke patients in July...